Cooley-Repped Life Sciences Group Prices $121M Offering
A Cooley-led biopharmaceutical group said Tuesday it has priced a $121 million follow-on public offering to help it continue researching treatments for autoimmune diseases....To view the full article, register now.
Already a subscriber? Click here to view full article